Management of neurogenic bladder in children. In: Guidelines on paediatric urology.

GUIDELINE TITLE
Management of neurogenic bladder in children. In: Guidelines on paediatric urology.

BIBLIOGRAPHIC SOURCE(S)
Management of neurogenic bladder in children. In: Tekgül S, Riedmiller H, Gerharz E, Hoebeke P, Kocvara R, Nijman R, Radmayr Chr, Stein R. Guidelines on paediatric urology. Arnhem, The Netherlands: European Association of Urology, European Society for Paediatric Urology; 2009 Mar. p. 31-41. [83 references]

GUIDELINE STATUS
This is the current release of the guideline.

This guideline updates a previous version: Management of neurogenic bladder in children. In: Tekgül S, Riedmiller H, Gerharz E, Hoebeke P, Kocvara R, Nijman R, Radmayr C, Stein R. Guidelines on paediatric urology. Arnhem, The Netherlands: European Association of Urology, European Society for Paediatric Urology; 2008 Mar. p. 34-43.

** REGULATORY ALERT **
FDA WARNING/REGULATORY ALERT
Note from the National Guideline Clearinghouse: This guideline references a drug(s) for which important revised regulatory and/or warning information has been released.

August 3, 2009 - Onabotulinum toxin A (Botox/Botox Cosmetic), Abobotulinum toxin A (Dysport) and Rimabotulinum toxin B (Myobloc): The U.S. Food and Drug Administration (FDA) notified healthcare professionals of changes to the established drug names for Botox/Botox Cosmetic, Dysport and Myobloc to reinforce individual potencies and prevent medication errors, and provided recommendations for healthcare professionals to consider, plus information for patients, family members, and caregivers.

abrir aquí para acceder al documento NGC AHRQ completo:
http://www.guideline.gov/summary/summary.aspx?ss=15&doc_id=14433&nbr=&string=